Combining Erbitux with chemotherapy significantly extends survival rates for colon cancer patients who have a specific genetic profile, according to results of the CRYSTAL trial. Study data showed patients with the normal, or wild-type, version of the KRAS gene had median survival rates of 23.5 months, compared with 20 months on chemotherapy alone.

Full Story:

Related Summaries